[{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nelarabine","moa":"||DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nelarabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Eversana","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nelarabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shorla Oncology \/ Eversana","highestDevelopmentStatusID":"15","companyTruncated":"Shorla Oncology \/ Eversana"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"St. Jude Children's Research Hospital \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ AbbVie Inc"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nelarabine","moa":"||DNA polymerase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Nelarabine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Chia Tai Tianqing Pharmaceutical Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 30, 2024

                          Lead Product(s) : Nelarabine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          St. Jude Children's Research Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Nelarabine, generic version of Arranon injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia and lymphoma in adult & pediatric patients.

                          Product Name : Arranon-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 08, 2024

                          Lead Product(s) : Nelarabine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older.

                          Product Name : Nelarabine-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 16, 2023

                          Lead Product(s) : Nelarabine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Eversana

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Nelarabine injection is generic version of Arranon®, granted competitive generic therapy (CGT) designation a chemotherapy drug that can be used to treat certain type of leukemia and lymphoma by slowing or stopping the growth of cancer cells.

                          Product Name : Nelarabine-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 18, 2021

                          Lead Product(s) : Nelarabine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          St. Jude Children's Research Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          St. Jude Children's Research Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          August 10, 2015

                          Lead Product(s) : Dexamethasone,Panobinostat lactate,Vincristine Sulfate,Mitoxantrone,Peg L asparaginase,Bortezomib,Methotrexate,Hydrocortisone,Cytarabine,Mercaptopurine,Nelarabine,Cyclophosphamide,Etoposide,Clofarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Novartis Pharmaceuticals Corporation | Spectrum Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          MD Anderson Cancer Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 29, 2010

                          Lead Product(s) : Nelarabine,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank